|
Jun 3
|
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
|
|
May 20
|
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
|
|
May 16
|
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Mar 28
|
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
|
|
Mar 26
|
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
|
|
Mar 25
|
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|